Company Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide.
It operates in two segments, Diabetes and Obesity care, and Biopharm.
The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.
The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy.
The company collaboration agreements with Gilead Sciences, Inc.
Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease.
The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
| Country | DK |
| IPO Date | Apr 30, 1981 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 71,880 |
| CEO | Lars Fruergaard Jorgensen |
Contact Details
Address: Novo Allé 1 Bagsvaerd, DK | |
| Website | https://www.novonordisk.com |
Stock Details
| Ticker Symbol | NVO |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000353278 |
| CUSIP Number | 670100205 |
| ISIN Number | US6701002056 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Lars Fruergaard Jorgensen | President, Chief Executive Officer & Member of Management Board |
| Karsten Munk Knudsen | Executive Vice President, Chief Financial Officer & Member of the Management Board |
| Camilla Sylvest | Executive Vice President of Commercial Strategy & Corporate Affairs and Member of the Management Board |
| Douglas J. Langa | Executive Vice President of North America Operations & Member of Management Board |
| Dr. Marcus Schindler Ph.D. | EVice President of Research & Early Development, Chief Scientific Officer & Member of the Management Board |
| Dr. Martin Holst Lange | Executive Vice President of Development & Member of the Management Board |
| Henrik Ehlers Wulff | Executive Vice President of Product Supply, Quality & IT and Member of the Management Board |
| Ludovic Helfgott | Executive Vice President, Head of Rare Disease & Member of Management Board |
| Maziar Mike Doustdar | Executive Vice President of International Operations & Member of the Management Board |
| Tania Sabroe | Executive Vice President of Global People & Organisation and Member of Management Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | 6-K | Filing |
| Dec 20, 2024 | 6-K | Filing |
| Dec 18, 2024 | 6-K | Filing |
| Dec 16, 2024 | 6-K | Filing |
| Dec 16, 2024 | 6-K | Filing |
| Dec 13, 2024 | 6-K | Filing |
| Dec 09, 2024 | 6-K | Filing |
| Dec 06, 2024 | 6-K | Filing |
| Dec 02, 2024 | 6-K | Filing |
| Nov 25, 2024 | 6-K | Filing |